TP508 (rusalatide) prices_
2 vendors list TP508 (rusalatide). Too few publish a comparable price to give a range. Last read Oct 20, 2026.
A 23-residue copy of one stretch of thrombin, the clotting enzyme, with no clotting activity of its own. It sped wrist-fracture healing in a 90-patient trial, then failed a 503-patient phase 3 and a 274-patient dose-finding trial.
Every vial, cheapest per milligram first
Vials come in different sizes, so price per mg is the only column that compares like with like.- Ruo BioTP-508 (Rusalatide) 10mg$88.00
- Disguised AlphaTP-508$119.99
| Vendor | Size | Price | Per mg | Availability | Checked | Link |
|---|---|---|---|---|---|---|
| Ruo Bio TP-508 (Rusalatide) 10mg | 10 mg | $88.00 | $8.80 | in stock | Oct 20, 2026 | View |
| Disguised Alpha TP-508 | 10 mg | $119.99 | $12.00 | out of stock | Oct 18, 2026 | View°code PEPTIDEDECODING saves 10% |
We earn from these links. It never changes a price or a position here.
Vendor by vendor
What each site was showing when we read it, and how it prices against the rest.Does not name a testing lab on this product's page.
Coverage record →Names its testing lab: ILS Laboratories (San Diego, CA; ISO/IEC 17025); COA per batch in a COA portal.
Coverage record →Three things price per mg does not tell you
A cheap milligram is only cheap if the vial holds it.The label is a claim, not a measurement
Every per mg number here divides the price by the milligrams printed on the vial. Testing labs regularly find vials that weigh less than the label says.
Shipping and card fees are not in these numbers
Shipping is often flat, so it hurts small orders most. Several vendors add a card fee and discount for crypto. Two offers a dollar apart can swap places at checkout.
Bigger vials look cheaper and go off just as fast
A bigger vial costs less per mg and expires on the same schedule. Once mixed, most people work to about 28 days in the fridge, so the saving only counts if you finish it.
What you are actually buying
Regulatory status changes what a price means.
Investigational
TP508 has never been approved by any regulator, anywhere, for any indication: no FDA application, no EMA marketing authorization, no approval in the UK, Japan, China or India, and no designation such as orphan drug or fast track has been found. Darrell Carney discovered it at the University of Texas Medical Branch at Galveston, and Chrysalis BioTechnology of Galveston held the Chrysalin assets through the 1990s. On August 5, 2004 OrthoLogic Corp. bought substantially all of that company's assets, including an exclusive worldwide license to Chrysalin for all medical indications, and expensed $25.8 million of in-process research. The phase 3 in wrist fracture reported failure on March 15, 2006 and the phase 2b was stopped that August; the company gave up running its own human trials, wrote off $2.1 million of Chrysalin patent costs, began doing business as Capstone Therapeutics on October 1, 2008 and was formally renamed Capstone Therapeutics Corp. on May 21, 2010. On January 20, 2012 Capstone announced it would end all Chrysalin development and return the patents to the university, effective March 1, 2012, keeping no rights. Chrysalis BioTherapeutics, Carney's company in Galveston, now holds a worldwide license from the University of Texas System and the medical branch; BARDA contract HHSO100201900016C added $10.4 million of options on December 1, 2020, taking total funding past $21 million, NIAID funded a cutaneous radiation injury agreement in 2024, and the FDA cleared an IND for acute lung failure, announced on September 26, 2023. The radiation program is being pursued under the FDA Animal Rule, and the company's own pipeline page shows every indication at 0% progress with possible approval named as early as 2027.
Full TP508 (rusalatide) record →Nobody stands behind a research vial
There is no pharmacist behind it, no dispensing record, and nobody on the hook for what is inside. The lab report is the whole quality system, which is why it sits next to the price here.
Research use only is a claim the seller has to keep making. A vendor that adds dosing instructions, health claims, or personal-use wording has stepped outside the framework it relies on, and that says something about the seller.
What customs and carriers do varies by state and by shipper. This describes how these products are sold and is not legal advice.
Before the vial arrives
What actually shows up, and the vial math that decides which size is the better buy.Frozen dry, refrigerated wet
Freeze-dried powder keeps for a long time in the freezer and for months in the fridge. Once liquid goes in, most people work to about 28 days in the fridge, away from light.
Bacteriostatic water and insulin syringes are extra
What arrives is powder in a sealed vial. Water goes down the inside wall rather than onto the powder, and the vial is swirled instead of shaken. Neither the water nor the syringes are in the prices above.
The bigger vial is only cheaper if you finish it
A larger TP508 (rusalatide) vial costs less per mg and expires on the same schedule once mixed. The saving is real only when the vial runs out inside that window.
Nothing on this page tells you what to take. Full walkthroughs live in the guides.
How this table is built
What decides the order of the rows, and who gets to be in them.Cheapest per mg first, and nothing else
Rows sort on one number. There is no combined score and no weighting, so no vendor can be pushed up the table by a rating you cannot check.
Doing badly does not get a vendor removed
Vendors that publish nothing stay in the table, marked. Taking them out would make the market look tidier than we found it.
Every price has a date on it
Prices are read off public catalog pages and saved with the date. If a check runs late the row says so instead of showing an old price as current.
Sorting never reads who pays us
Commissioned links are marked on the row and listed on the disclosure page. They never move a listing up or down the table.
How these prices are collected
Prices on this site are read from vendor websites on the dates shown. A starting tag means the vendor publishes only a from price for that product. A wall means the seller hides the price behind an account, and we publish that fact rather than hide the gap.
We report prices and never rate or score an offer. There is no value grade, no ranking of vendors by our opinion. A row carries its size, its price, its price per milligram, and any plain fact about the listing worth knowing.
When a vendor's site disappears, its rows stay in the tables as a dated record, drop out of every count, price range and ranking, and lose their links. Ninety days after a vendor's site disappears, its rows leave these tables and remain in our records.
Some vendors pay this site a commission when you buy through our links. Every one of those links is marked, and every vendor with that arrangement is labeled on the vendor page. Commissions never change the prices we show, the order of any table, a vendor's badge, or anything in the audit record. The data is collected the same way for every vendor, paid or not.
We accept no payment for coverage, placement, or ratings. Warning letters come from fda.gov. If a paying vendor earns a bad mark, the mark stays.
Questions about buying tp508 (rusalatide)
Cost, sizes, and how this table works.How much does TP508 (rusalatide) cost?+
We track 2 listings across 2 vendors, which is too few to publish a reliable per milligram range. The table above shows every price we have read.
Why is the same vial so much cheaper at one vendor?+
Vial size, sale cycles, payment method discounts, and how much testing evidence a seller publishes all move the number. A cheap milligram is only cheap if the vial holds what the label claims, which no price column can tell you.
Do you make money if I buy?+
Sorting never reads whether a vendor pays us. Any commissioned link is marked on the row and listed on the disclosure page, and it never changes where a listing lands in the table.
Is tp508 (rusalatide) legal to buy?+
TP508 has never been approved by any regulator, anywhere, for any indication: no FDA application, no EMA marketing authorization, no approval in the UK, Japan, China or India, and no designation such as orphan drug or fast track has been found. Darrell Carney discovered it at the University of Texas Medical Branch at Galveston, and Chrysalis BioTechnology of Galveston held the Chrysalin assets through the 1990s. On August 5, 2004 OrthoLogic Corp. bought substantially all of that company's assets, including an exclusive worldwide license to Chrysalin for all medical indications, and expensed $25.8 million of in-process research. The phase 3 in wrist fracture reported failure on March 15, 2006 and the phase 2b was stopped that August; the company gave up running its own human trials, wrote off $2.1 million of Chrysalin patent costs, began doing business as Capstone Therapeutics on October 1, 2008 and was formally renamed Capstone Therapeutics Corp. on May 21, 2010. On January 20, 2012 Capstone announced it would end all Chrysalin development and return the patents to the university, effective March 1, 2012, keeping no rights. Chrysalis BioTherapeutics, Carney's company in Galveston, now holds a worldwide license from the University of Texas System and the medical branch; BARDA contract HHSO100201900016C added $10.4 million of options on December 1, 2020, taking total funding past $21 million, NIAID funded a cutaneous radiation injury agreement in 2024, and the FDA cleared an IND for acute lung failure, announced on September 26, 2023. The radiation program is being pursued under the FDA Animal Rule, and the company's own pipeline page shows every indication at 0% progress with possible approval named as early as 2027.
How current are these prices?+
Every price is read off a public catalog page and stored with its date; this compound was last read Oct 20, 2026. Nothing is overwritten, so a stale row says so rather than pretending to be current.
